Quote | Elevation Oncology Inc. (NASDAQ:ELEV)
Last: | $2.72 |
---|---|
Change Percent: | 3.03% |
Open: | $2.69 |
Close: | $2.64 |
High: | $2.75 |
Low: | $2.6 |
Volume: | 203,464 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Elevation Oncology Inc. (NASDAQ:ELEV)
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer PR Newswire -- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GS...
2024-05-27 06:35:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s always a good idea to fortify your portfolio with blue-chip stocks – solid, dependable names that you can bank on to deliver each quarter. But you can’t stop there...
Message Board Posts | Elevation Oncology Inc. (NASDAQ:ELEV)
Subject | By | Source | When |
---|---|---|---|
$ELEV Price gaining | Invest-in-America | investorshub | 04/22/2023 1:49:51 PM |
$ELEV MomentumIts gaining | Mt. Blanc | investorshub | 04/19/2023 3:56:59 PM |
Price trading last trade up | RNsidersbuying | investorshub | 04/19/2023 8:07:39 AM |
MomentumIts trading | Mt. Blanc | investorshub | 04/18/2023 12:38:48 AM |
are we finally gonna see some action | Mt. Blanc | investorshub | 04/16/2023 11:11:06 PM |
News, Short Squeeze, Breakout and More Instantly...
Elevation Oncology Inc. Company Name:
ELEV Stock Symbol:
NASDAQ Market:
Elevation Oncology Inc. Website:
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer PR Newswire -- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GS...
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference PR Newswire BOSTON , May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therap...